Why Fractyl Health, Inc.’s (GUTS) Stock Is Up 6.38%
As of Friday, October 09, Fractyl Health, Inc.’s GUTS share price has surged by 6.38%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Commentary & Analysis
Why Fractyl Health, Inc.’s (GUTS) Stock Is Down 5.53%
As of Thursday, October 08, Fractyl Health, Inc.’s GUTS share price has dipped by 5.53%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Fractyl Health, Inc.’s (GUTS) Stock Is Down 8.15%
As of Friday, October 02, Fractyl Health, Inc.’s GUTS share price has dipped by 8.15%, which has investors questioning if this is right time to buy.Michael Rose
Why Fractyl Health, Inc.’s (GUTS) Stock Is Down 13.45%
As of Thursday, October 01, Fractyl Health, Inc.’s GUTS share price has dipped by 13.45%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Fractyl Health, Inc.’s (GUTS) Stock Is Down 16.77%
As of Thursday, October 01, Fractyl Health, Inc.’s GUTS share price has dipped by 16.77%, which has investors questioning if this is right time to buy.Omar Beirat
Financial Summary
| Share Statistics | GUTS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $58.6 | $385.5 | 17% |
|
| Shares Out (Mil) | 13.2 | 40.8 | 24% |
|
| Institutional Ownership | 97.2% | 83.0% | 73% |
|
| Float (Mil) | 12.1 | 35.5 | 22% |
|
| Beta | 2.42 | 0.85 | 95% |
|
| Avg Daily Volume (000s) | 220 | 321 | 45% |
|
| Price Change (52-week) |
(73.7%) | 64.6% | 10% |
|
| Growth | GUTS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 11.8% | na |
|
| Net Income (5yr) | (35.8%) | (5.5%) | 11% |
|
| EPS (5yr) | 39.1% | 10.2% | 88 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (57.0%) | (15.5%) | 5% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 5 | |
| Current EPS | ($1.495) | ($3.975) | ($4.778) | |
| Month Ago EPS | ($1.470) | ($3.960) | ($5.260) | |
| # Rev Up | 2 | 0 | 2 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($1.660) | ($4.680) | ($5.980) | |
| Year/Year Chg | (22.6%) | (82.2%) | (88.1%) | |
| Financials | GUTS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $155 | na |
|
| Net Income (TTM) (Mil) | ($106) | ($9) | 11% |
|
| EPS (TTM) | ($9.705) | ($0.400) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($82) | ($2) | 7% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $56 | $27 | 40% |
|
| Enterprise Value (Q1) (Mil) | $74 | $418 | 19% |
|
| Valuation | GUTS | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.69 | na |
|
| P/E | na | 24.8 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.5 | na |
|
| Ratios | GUTS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 58.5% | na |
|
| Net Margin | na | (6.9%) | na |
|
| ROA | (146.8%) | (12.2%) | 3% |
|
| ROE | na | (10.5%) | na |
|
| Liabilities to Assets | 102.0% | 47.2% | 94% |
|
| F-Score | 2 | 4 | 7% |
|
Fractyl Health, Inc. did not pass any screens on 10/9/2026.
